Cargando…

Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures

OBJECTIVE: The efficacy of pre-exposure prophylaxis (PrEP) in HIV will diminish with poor adherence; pharmacologic measures of drug exposure have proven critical to PrEP trial interpretation. We assessed drug exposure in hair against other pharmacologic and more routinely used measures to assess pil...

Descripción completa

Detalles Bibliográficos
Autores principales: Baxi, Sanjiv M., Liu, Albert, Bacchetti, Peter, Mutua, Gaudensia, Sanders, Eduard J., Kibengo, Freddie M., Haberer, Jessica E., Rooney, James, Hendrix, Craig W., Anderson, Peter L., Huang, Yong, Priddy, Frances, Gandhi, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262724/
https://www.ncbi.nlm.nih.gov/pubmed/25296098
http://dx.doi.org/10.1097/QAI.0000000000000386
_version_ 1782348457509388288
author Baxi, Sanjiv M.
Liu, Albert
Bacchetti, Peter
Mutua, Gaudensia
Sanders, Eduard J.
Kibengo, Freddie M.
Haberer, Jessica E.
Rooney, James
Hendrix, Craig W.
Anderson, Peter L.
Huang, Yong
Priddy, Frances
Gandhi, Monica
author_facet Baxi, Sanjiv M.
Liu, Albert
Bacchetti, Peter
Mutua, Gaudensia
Sanders, Eduard J.
Kibengo, Freddie M.
Haberer, Jessica E.
Rooney, James
Hendrix, Craig W.
Anderson, Peter L.
Huang, Yong
Priddy, Frances
Gandhi, Monica
author_sort Baxi, Sanjiv M.
collection PubMed
description OBJECTIVE: The efficacy of pre-exposure prophylaxis (PrEP) in HIV will diminish with poor adherence; pharmacologic measures of drug exposure have proven critical to PrEP trial interpretation. We assessed drug exposure in hair against other pharmacologic and more routinely used measures to assess pill-taking. DESIGN: Participants were randomized to placebo, daily PrEP, or intermittent PrEP to evaluate safety and tolerability of daily versus intermittent tenofovir/emtricitabine (TFV/FTC) in 2 phase II PrEP clinical trials conducted in Africa. Different measures of drug exposure, including self-report, medication event monitoring system (MEMS)-caps openings, and TFV/FTC levels in hair and other biomatrices were compared. METHODS: At weeks 8 and 16, self-reported pill-taking, MEMS-caps openings, and TFV/FTC levels in hair, plasma, and peripheral blood mononuclear cells (PBMCs) were measured. Regression models evaluated predictors of TFV/FTC concentrations in the 3 biomatrices; correlation coefficients between pharmacologic and nonpharmacologic measures were calculated. Both trials were registered on ClinicalTrials.gov (NCT00931346/NCT00971230). RESULTS: Hair collection was highly feasible and acceptable (100% in week 8; 96% in week 16). In multivariate analysis, strong associations were seen between pharmacologic measures and MEMS-caps openings (all P < 0.001); self-report was only weakly associated with pharmacologic measures. TFV/FTC hair concentrations were significantly correlated with levels in plasma and PBMCs (correlation coefficients, 0.41–0.86, all P < 0.001). CONCLUSIONS: Measuring TFV/FTC exposure in small hair samples in African PrEP trials was feasible and acceptable. Hair levels correlated strongly with PBMC, plasma concentrations, and MEMS-caps openings. As in other PrEP trials, self-report was the weakest measure of exposure. Further study of hair TFV/FTC levels in PrEP trials and demonstration projects to assess adherence/exposure is warranted.
format Online
Article
Text
id pubmed-4262724
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher JAIDS Journal of Acquired Immune Deficiency Syndromes
record_format MEDLINE/PubMed
spelling pubmed-42627242014-12-16 Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures Baxi, Sanjiv M. Liu, Albert Bacchetti, Peter Mutua, Gaudensia Sanders, Eduard J. Kibengo, Freddie M. Haberer, Jessica E. Rooney, James Hendrix, Craig W. Anderson, Peter L. Huang, Yong Priddy, Frances Gandhi, Monica J Acquir Immune Defic Syndr Clinical Science OBJECTIVE: The efficacy of pre-exposure prophylaxis (PrEP) in HIV will diminish with poor adherence; pharmacologic measures of drug exposure have proven critical to PrEP trial interpretation. We assessed drug exposure in hair against other pharmacologic and more routinely used measures to assess pill-taking. DESIGN: Participants were randomized to placebo, daily PrEP, or intermittent PrEP to evaluate safety and tolerability of daily versus intermittent tenofovir/emtricitabine (TFV/FTC) in 2 phase II PrEP clinical trials conducted in Africa. Different measures of drug exposure, including self-report, medication event monitoring system (MEMS)-caps openings, and TFV/FTC levels in hair and other biomatrices were compared. METHODS: At weeks 8 and 16, self-reported pill-taking, MEMS-caps openings, and TFV/FTC levels in hair, plasma, and peripheral blood mononuclear cells (PBMCs) were measured. Regression models evaluated predictors of TFV/FTC concentrations in the 3 biomatrices; correlation coefficients between pharmacologic and nonpharmacologic measures were calculated. Both trials were registered on ClinicalTrials.gov (NCT00931346/NCT00971230). RESULTS: Hair collection was highly feasible and acceptable (100% in week 8; 96% in week 16). In multivariate analysis, strong associations were seen between pharmacologic measures and MEMS-caps openings (all P < 0.001); self-report was only weakly associated with pharmacologic measures. TFV/FTC hair concentrations were significantly correlated with levels in plasma and PBMCs (correlation coefficients, 0.41–0.86, all P < 0.001). CONCLUSIONS: Measuring TFV/FTC exposure in small hair samples in African PrEP trials was feasible and acceptable. Hair levels correlated strongly with PBMC, plasma concentrations, and MEMS-caps openings. As in other PrEP trials, self-report was the weakest measure of exposure. Further study of hair TFV/FTC levels in PrEP trials and demonstration projects to assess adherence/exposure is warranted. JAIDS Journal of Acquired Immune Deficiency Syndromes 2015-01-01 2014-12-11 /pmc/articles/PMC4262724/ /pubmed/25296098 http://dx.doi.org/10.1097/QAI.0000000000000386 Text en Copyright © 2014 by Lippincott Williams & Wilkins This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Science
Baxi, Sanjiv M.
Liu, Albert
Bacchetti, Peter
Mutua, Gaudensia
Sanders, Eduard J.
Kibengo, Freddie M.
Haberer, Jessica E.
Rooney, James
Hendrix, Craig W.
Anderson, Peter L.
Huang, Yong
Priddy, Frances
Gandhi, Monica
Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures
title Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures
title_full Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures
title_fullStr Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures
title_full_unstemmed Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures
title_short Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures
title_sort comparing the novel method of assessing prep adherence/exposure using hair samples to other pharmacologic and traditional measures
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262724/
https://www.ncbi.nlm.nih.gov/pubmed/25296098
http://dx.doi.org/10.1097/QAI.0000000000000386
work_keys_str_mv AT baxisanjivm comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures
AT liualbert comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures
AT bacchettipeter comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures
AT mutuagaudensia comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures
AT sanderseduardj comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures
AT kibengofreddiem comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures
AT habererjessicae comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures
AT rooneyjames comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures
AT hendrixcraigw comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures
AT andersonpeterl comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures
AT huangyong comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures
AT priddyfrances comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures
AT gandhimonica comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures